Drugs and Devices

FDA approves new treatment for patients with hemophilia B

On March 4, the Food and Drug Administration (FDA) approved Idelvion, Coagulation Factor IX (Recombinant), Albumin Fusion Protein, for use in children and adults with Hemophilia B. Idelvion is the first coagulation factor-albumin fusion protein product to be approved. Read more


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares